Stem Cells for Knee Osteoarthritis: What the Evidence Actually Shows

If your knees ache going down stairs, you have probably seen the ads: a single injection of stem cells to "regrow" your worn cartilage and undo years of wear. It is one of the most-searched ideas in joint health — and also one of the most over-promised. This is an honest walk through what stem cells are, what the research genuinely shows for knee osteoarthritis today, and, just as importantly, what no responsible clinic can promise you yet.

What knee osteoarthritis actually is

Osteoarthritis (OA) is the most common joint condition in the world — an estimated 528 million people were living with it in 2019, and the knee is the single most affected joint ¹. It is often described as "wear and tear," but that undersells it. OA is the whole joint slowly changing: the cartilage that cushions the bone ends thins, the bone underneath adapts and hardens (a finding called subchondral sclerosis), and the surrounding tissues become inflamed and stiff.

That matters here because cartilage, once it is significantly worn, does not simply grow back on its own — it has almost no blood supply and limited capacity to repair. That biological reality is exactly why the idea of adding repair cells is so appealing, and why it deserves a careful, honest look rather than a sales pitch. (For the bigger picture on the condition itself — symptoms, causes and everyday care — see our plain-language guide to knee osteoarthritis.)

What are mesenchymal stem cells?

The cells used in most knee studies are mesenchymal stem cells (MSCs), sometimes called mesenchymal stromal cells. They are drawn from sources such as bone marrow, fat tissue, or donated umbilical cord, then concentrated and injected into the joint.

Here is the part the marketing usually skips. For years the assumption was that injected MSCs would turn into fresh cartilage. The current scientific thinking is mostly different: MSCs appear to act largely by signalling — releasing factors that calm inflammation and influence the joint's own cells — rather than by becoming new tissue themselves. In other words, their main role may be changing the joint's environment, not rebuilding it brick by brick.

Where do the cells come from?

Not all "stem cell" treatments are the same, and the source matters. Broadly, there are two routes. Autologous cells come from your own body — usually concentrated from bone marrow or fat, then returned to the joint in the same visit. Because they are your own, rejection is not a concern, though the amount and quality of cells can vary with age and health. Allogeneic cells come from a screened donor, most often umbilical cord tissue donated after a healthy birth; these are younger cells available in more consistent quantities, prepared under laboratory conditions.

Neither is automatically "better" — they are different tools with different trade-offs, and which (if either) is appropriate is part of a medical assessment, not a menu choice. What should always be consistent is how the cells are handled: proper screening, sterile preparation, and a regulated setting. Anywhere vague about where its cells come from or how they are processed is telling you something important.

What does the current evidence show?

This is where honesty matters most. The research is genuinely promising, and it is genuinely unsettled — both things are true at once.

A 2026 systematic review and meta-analysis pooled 28 randomised controlled trials of intra-articular MSC therapy for knee OA. On average, it found meaningful improvements in pain and in function compared with control treatments ³. That is a real, encouraging signal from the best kind of evidence we have.

But the same review is candid about the catch: the trials are heterogeneous — they use different cell sources, different preparations, different doses and techniques — and their results are inconsistent ³. A treatment that helps in one well-run trial may use a completely different preparation from the clinic down the road advertising "stem cells." Averages across trials are not a guarantee for any one person, and "promising" is not the same as "proven and standardised."

So here is the fair summary:

Encouraging early evidence — not settled medicine.

For context, mainstream osteoarthritis guidance still centres on movement, strength, weight management and symptom relief as the foundation of care ² — regenerative options sit alongside that conversation, not in place of it.

Who is it being studied for?

In the research, the people who tend to be studied are those with mild-to-moderate knee OA who still have some cartilage to work with, rather than bone-on-bone end-stage joints. But eligibility is genuinely individual — it depends on your imaging, your symptoms, your activity goals, your other health conditions, and what you have already tried.

That is the honest reason these decisions can only be made in a consultation, not from an article or an ad. A good assessment is as much about ruling things out and setting realistic expectations as it is about offering a procedure.

What it cannot promise

A few things worth saying plainly, because the internet rarely does:

• It is not a guaranteed cartilage regrowth. The evidence points more toward symptom and function improvement than toward rebuilding a worn joint.
• Results vary a lot between people and between preparations — your outcome is not the trial average.
• In much of the world it remains investigational, not a standardised, fully approved routine treatment — and anywhere advertising guaranteed cures or "miracle" outcomes is a red flag, not a recommendation.
• It does not replace the basics. Strength, movement and weight management still do much of the heavy lifting in knee OA.

How we think about it at Cureon

The most common thing we are asked is some version of: "Can you just inject stem cells and fix my knee?" Our honest answer is that regenerative approaches are an area we take seriously and follow closely — and also one where we would rather set realistic expectations than sell certainty. We start by understanding your joint, your imaging and what you actually want to be able to do, and we are comfortable saying when conservative care is the more sensible first step, or when something is not a good fit. If regenerative options are worth discussing in your case, that is a conversation with a physician — never a checkout. You can read more about how we approach this field in our complete guide to regenerative medicine.

Common questions

Will stem cells regrow my cartilage? That is the popular hope, but current evidence points more toward reduced pain and improved function than toward regrowing a worn joint. Be cautious of anyone promising full cartilage regeneration.

Is it approved and standard treatment? In much of the world it is still considered investigational rather than a routine, fully approved therapy. That does not mean it is worthless — it means it belongs in a careful, individual discussion, not an impulse purchase.

Am I a candidate? It depends on your imaging, symptoms, goals and health history. People with some cartilage remaining are more typically studied than those with end-stage, bone-on-bone joints — but only an assessment can answer this for you.

Does it replace exercise and weight management? No. Those remain the foundation of knee osteoarthritis care, whatever else you consider ².

Key takeaway

Stem cell therapy for knee osteoarthritis is one of the more promising areas in joint care — recent pooled trial data show real improvements in pain and function on average — but it is early, inconsistent, and frequently over-sold ³. The grown-up version of the story is hopeful and honest at the same time: worth understanding, worth discussing with a physician, and not worth believing the miracle ads. If you want to know what makes sense for your knee, that starts with a proper assessment.